Problems, both manufacturing and financial, with an Austrian fill-finish firm has resulted in a partial hold of a trial of Innate Pharma, the French biotech that has a list of development deals with some of the biggest players in pharma.
read moreIan Read may have shed all his responsibilities at Pfizer, but he clearly has no intention of retreating to a quiet retirement. The pharma giant’s former CEO and executive chairman is joining The Carlyle Group’s healthcare team as a deal scout,
read moreBefore it closed the Bristol-Myers Squibb merger, Celgene last year inked a $55 million settlement with plaintiffs and payers over allegations it blocked multiple myeloma drug competition. Now, something has changed. The company backed out of the deal in late
read moreThe product will be officially announced prior to launch. More: Hikma, Arecor set to co-develop new injectable meds Source: News
read morePrevious studies have found that people on long-term treatment for psychotic illnesses have lower cancer rates. More: Could Prozac help fight neuroblastoma? Source: News
read moreThe Novartis drug can bind to IgE with an 88-fold higher affinity than Xolair. More: Ligelizumab continues to trump Xolair in chronic spontaneous urticaria Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals